Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : MP101
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ema Greenlights Mitochon Pharmaceuticals To Initiate Phase I/IIa Biomarker Study
Details : MP101 is a once-daily, oral brain penetrant mitochondrial stimulator under phase 1/2 clinical development for amyotrophic lateral sclerosis, multiple sclerosis, and Huntington’s disease.
Product Name : MP101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 01, 2024
Lead Product(s) : MP101
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable